Overview
- The study evaluated records from the ADAPT infant peanut oral immunotherapy program and found 35% of challenged infants had no reaction and could have their allergy label removed.
- Researchers reviewed 1,275 infants assessed between April 2024 and October 2025 and report 778 underwent supervised oral food challenges at a median age of about 13 months.
- Among infants who did react, 65% showed symptoms during challenge and 12% experienced anaphylaxis that was managed by clinical teams, after which roughly 97–97.5% began oral immunotherapy at challenge-guided doses.
- Authors and ADAPT leads say a supervised oral food challenge should be considered before starting infant peanut immunotherapy because history plus skin or blood tests over-diagnose many babies.
- Wider use of challenge-directed care faces practical barriers including limited ADAPT capacity, uneven regional access, out-of-pocket costs in private care and no dedicated Medicare item to reimburse resource-intensive challenges.